Novartis Ag (NVS) Non-Current Assets (2009 - 2025)
Novartis Ag's (NVS) quarterly Non-Current Assets came in at $80.5 billion in Q4 2025, up 10.96% year-on-year from $72.5 billion in Q4 2024, and up 2.59% quarter-over-quarter from $78.5 billion in Q2 2025.
Novartis Ag (NVS) Non-Current Assets (2009 - 2025) Analysis & Trends
Novartis Ag has disclosed Non-Current Assets across 12 years of filings, most recently posting $80.5 billion for Q4 2025.
- Non-Current Assets for Q4 2025 came in at $80.5 billion, up 10.96% year-over-year; the trailing twelve-month figure through Dec 2025 was $80.5 billion (up 10.96% YoY), and the FY2025 annual result was $80.5 billion, up 10.96% from the prior year.
- Non-Current Assets came in at $80.5 billion for Q4 2025 at Novartis Ag, up from $78.5 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $86.1 billion in Q4 2021 to a low of $57.5 billion in Q2 2021.
- The 5-year median for Non-Current Assets is $78.0 billion (2023), against an average of $75.9 billion.
- Across the five-year window, Non-Current Assets jumped 47.42% in 2022 and retreated 13.76% in 2023, its largest moves.
- Novartis Ag's Non-Current Assets stood at $86.1 billion in 2021, then decreased by 6.43% to $80.5 billion in 2022, then declined by 13.76% to $69.5 billion in 2023, then climbed by 4.43% to $72.5 billion in 2024, then gained by 10.96% to $80.5 billion in 2025.
- The last three Non-Current Assets figures came in at $80.5 billion (Q4 2025), $78.5 billion (Q2 2025), and $72.5 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 60.81 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 61.74 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 141.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 102.93 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 59.27 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 80.49 Bn |
| Jun 30, 2025 | 78.46 Bn |
| Dec 31, 2024 | 72.54 Bn |
| Jun 30, 2024 | 71.81 Bn |
| Dec 31, 2023 | 69.46 Bn |
| Jun 30, 2023 | 77.49 Bn |
| Dec 31, 2022 | 80.54 Bn |
| Jun 30, 2022 | 84.77 Bn |
| Dec 31, 2021 | 86.08 Bn |
| Jun 30, 2021 | 57.50 Bn |
| Dec 31, 2020 | 98.11 Bn |
| Jun 30, 2020 | 55.70 Bn |
| Dec 31, 2019 | 88.87 Bn |
| Jun 30, 2019 | 53.80 Bn |
| Dec 31, 2018 | 110.00 Bn |
| Jun 30, 2018 | 57.80 Bn |
| Dec 31, 2017 | 104.87 Bn |
| Dec 31, 2016 | 105.19 Bn |
| Mar 31, 2010 | 59,995.00 |
| Dec 31, 2009 | 61,814.00 |